Adjuvant chemotherapy after gastric resection in node-positive cancer patients: a multicentre randomised study
1996

Chemotherapy After Stomach Surgery for Cancer

Sample size: 103 publication Evidence: moderate

Author Information

Author(s): B Neril, V de Leonardis, S Romano, F Andreoli, LM Pernice, L Bruno, D Borrelli, A Valeri, S Fabbroni, C Intini, G Cini

Primary Institution: University of Florence, Italy

Hypothesis

Does adjuvant chemotherapy improve survival in node-positive gastric cancer patients after surgery?

Conclusion

Adjuvant chemotherapy improves survival rates in node-positive gastric cancer patients after surgery.

Supporting Evidence

  • Patients receiving chemotherapy had a median survival of 20.4 months compared to 13.6 months for those who did not.
  • Only 10% of treated patients had recurrences compared to 38% of control patients.
  • Acute toxicity from chemotherapy was mild and well tolerated.

Takeaway

This study found that giving chemotherapy after stomach surgery helps patients live longer and have fewer cancer recurrences.

Methodology

103 patients were randomized to receive either chemotherapy or no treatment after gastric resection, with follow-up for 36 months.

Limitations

The study's final assessment requires completion of the trial, and the results may not apply to all gastric cancer patients.

Participant Demographics

Patients had histologically proven adenocarcinoma and were node-positive, with a Karnofsky score greater than 60.

Statistical Information

P-Value

p<0.01

Confidence Interval

1.29 to 3.66

Statistical Significance

p<0.01

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication